| IFRX Snapshot | |
|---|---|
| InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany. | |
| VALUATION DATA | |
| Market Capitalization | $81,848,000 | Price to Sales | 1.00 |
| Earnings per Share | $-0.8500 |
| PE Ratio | None |
| PRICE DATA | |
| Most Recent Close | $1.3900 |
| 52 Week High | $1400.01 |
| 52 Week Low | $0.802 |
| 50-Day Moving Average | $- |
| 200-Day Moving Average | $0.174 |
| All data are from Alpha Vantage as of today. For more infomation on IFRX see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search